The Effect of Low-Intensity Extracorporeal Shockwave Treatment on the Urinary Bladder in an Experimental Diabetic Rat Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Preclinical data increasingly support an impact of low-intensity extracorporeal shockwave therapy (Li-ESWT) on the bladder. We investigated the molecular effects of Li-ESWT on the bladder of a streptozotocin-induced diabetic rat model. Methods: Fifteen 8-week-old male Wistar rats were randomized into 3 groups: a control group (n=5), a group of diabetic rats without treatment (diabetes mellitus [DM], n=5) and a group of diabetic rats treated with Li-ESWT (DM-ESWT, n=5). A single intraperitoneal dose of streptozotocin (60 mg/kg) was used to induce diabetes. Twenty days after diabetes induction, each rat in the DM-ESWT group received 300 shockwaves with an energy flux density of 0.09 mJ/mm2. Sessions were repeated 3 times/week for 2 weeks, followed by a 2-week washout period. Total RNA from bladder tissue was extracted, cDNA was synthesized, and quantitative real-time polymerase chain reaction was performed to analyze the expression pattern of transient receptor potential vanilloid 1 (Trpv1), interleukin-1β (Il1b), and the muscarinic receptors M1, M2, and M3 (Chrm1, Chrm2, and Chrm3). Results: The expression of Trpv1, Il1b, and Chrm2 genes was significantly different between the 3 groups (P=0.002, P<0.0001, and P=0.011, respectively; 1-way analysis of variance). In the DM group, the expression of all genes was higher than in the control group, but statistical significance was observed only for Trpv1 and Il1b (P=0.002 and P<0.0001, respectively). Li-ESWT significantly reduced the expression of Il1b and Chrm2 (P=0.001 and P=0.011, respectively), whereas a nonsignificant tendency for reduced expression was noted for Trpv1 (P=0.069). Conclusions: The induction of diabetes was associated with increased expression of genes related to mechanosensation, inflammation/ ischemia, and contraction in the rat bladder. Li-ESWT reduced the expression of IL1b, Chrm2, and to a lesser extent Trpv1 toward the control levels, suggesting the therapeutic potential of this treatment modality for diabetic cystopathy.
Abstract
Purpose: Preclinical data increasingly support an impact of low-intensity extracorporeal shockwave therapy (Li-ESWT) on the bladder. We investigated the molecular effects of Li-ESWT on the bladder of a streptozotocin-induced diabetic rat model. Methods: Fifteen 8-week-old male Wistar rats were randomized into 3 groups: a control group (n=5), a group of diabetic rats without treatment (diabetes mellitus [DM], n=5) and a group of diabetic rats treated with Li-ESWT (DM-ESWT, n=5). A single intraperitoneal dose of streptozotocin (60 mg/kg) was used to induce diabetes. Twenty days after diabetes induction, each rat in the DM-ESWT group received 300 shockwaves with an energy flux density of 0.09 mJ/mm2. Sessions were repeated 3 times/week for 2 weeks, followed by a 2-week washout period. Total RNA from bladder tissue was extracted, cDNA was synthesized, and quantitative real-time polymerase chain reaction was performed to analyze the expression pattern of transient receptor potential vanilloid 1 (Trpv1), interleukin-1β (Il1b), and the muscarinic receptors M1, M2, and M3 (Chrm1, Chrm2, and Chrm3). Results: The expression of Trpv1, Il1b, and Chrm2 genes was significantly different between the 3 groups (P=0.002, P<0.0001, and P=0.011, respectively; 1-way analysis of variance). In the DM group, the expression of all genes was higher than in the control group, but statistical significance was observed only for Trpv1 and Il1b (P=0.002 and P<0.0001, respectively). Li-ESWT significantly reduced the expression of Il1b and Chrm2 (P=0.001 and P=0.011, respectively), whereas a nonsignificant tendency for reduced expression was noted for Trpv1 (P=0.069). Conclusions: The induction of diabetes was associated with increased expression of genes related to mechanosensation, inflammation/ ischemia, and contraction in the rat bladder. Li-ESWT reduced the expression of IL1b, Chrm2, and to a lesser extent Trpv1 toward the control levels, suggesting the therapeutic potential of this treatment modality for diabetic cystopathy.
참고문헌 (36)
- Sokolakis I, "The basic science behind low-intensity extracorporeal shockwave therapy for erectile dysfunction : a systematic scoping review of pre-clinical studies", J Sex Med, 16, pp.168~194 (2019)
- Sokolakis I, "Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction : a systematic review and meta-analysis of randomised controlled trials", Int J Impot Res, 31, pp.177~194 (2019)
- Chen YT, "Extracorporeal shock wave markedly alleviates radiation-induced chronic cystitis in rat", Am J Transl Res, 10, pp.1036~1052 (2018)
- Chuang YC, "Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model", Int Urol Nephrol, 51, pp.617~626 (2019)
- Chuang YC, "Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy", Neurourol Urodyn, 37, pp.708~715 (2018)
- Jin Y, "Endogenous stem cells were recruited by defocused low-energy shock wave in treating diabetic bladder dysfunction", Stem Cell Rev Rep, 13, pp.287~298 (2017)
- Huixi Li, "Treatment with low-energy shock wave alleviates pain in an animal model of uroplakin 3A-induced autoimmune interstitial cystitis", painful bladder syndrome, 2019, pp.60(5), 359~366[DOI]
- Wang HJ, "Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model", Neurourol Urodyn, 36, pp.1440~1447 (2017)
- Wittig L, "Diabetic bladder dysfunction : a review", Urology, 123, pp.1~6 (2019)
- Daneshgari F, "Diabetic bladder dysfunction : current translational knowledge", J Urol, 182(6 Suppl), pp.S18~S26 (2009)
- Wang HS, "Low-intensity extracorporeal shockwave therapy ameliorates diabetic underactive bladder in streptozotocin-induced diabetic rats", BJU Int, 122, pp.490~500 (2018)
- Yakhchalian N, "Hematological and serum biochemical analysis of streptozotocin-induced insulin dependent diabetes mellitus in male adult wistar rats", bioRxiv 2018:359844, ~ (2018)
- Arioglu Inan E, "A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models", Neurourol Urodyn, 37, pp.1212~1219 (2018)
- Nailong Cao, "Time-Dependent Changes of Urethral Function in Diabetes Mellitus: A Review", International Neurourology Journal, 23(2), pp.91~99 (2019), 대한배뇨장애요실금학회[DOI]
- Assaly-Kaddoum R, "Low intensity extracorporeal shock wave therapy improves erectile function in a model of type ii diabetes independently of NO", cGMP pathway, 2016, pp.196, 950~956
- Sokolakis I, "Effects of low-intensity shock wave therapy(LiST)on the erectile tissue of naturally aged rats", Int J Impot Res, 31, pp.162~169 (2019)
- Liu T, "Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy", Int J Impot Res, 31, pp.170~176 (2019)
- Qiu X, "Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model", J Sex Med, 10, pp.738~746 (2013)
- Lee WC, "Ba-WeiDie-Huang-Wan (Hachimi-jio-gan) can ameliorate ketamine-induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model", Neurourol Urodyn, 38, pp.2159~2169 (2019)
- Apostolidis A, "Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity", J Urol, 174, pp.977~982 (2005)
- Mukerji G, "Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain", J Urol, 176, pp.797~801 (2006)
- Gram DX, "TRPV1 : a potential therapeutic target in type 2 diabetes and comorbidities", Trends Mol Med, 23, pp.1002~1013 (2017)
- Gram DX, "TRPV1 antagonists as novel anti-diabetic agents: regulation of oral glucose tolerance and insulin secretion through reduction of low-grade inflammation?", Med Sci (Basel), 7, pp.82~ (2019)
- Sharopov BR, "TRPV1 alterations in urinary bladder dysfunction in a rat model of STZ-induced diabetes", Life Sci, 193, pp.207~213 (2018)
- Purves JT, "Inflammasomes in the urinary tract : a disease-based review", Am J Physiol Renal Physiol, 311, pp.F653~62 (2016)
- Wada J, "Innate immunity in diabetes and diabetic nephropathy", Nat Rev Nephrol, 12, pp.13~26 (2016)
- Oberbach A, "Free fatty acid palmitate impairs the vitality and function of cultured human bladder smooth muscle cells", PLoS One, 7, pp.e41026~ (2012)
- Ding H, "The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats", Int Urol Nephrol, 51, pp.253~260 (2019)
- Shin SJ, "Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes", PLoS One, 11, pp.e0165703~ (2016)
- Lin TL, "Aging and recurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes", Taiwan J Obstet Gynecol, 51, pp.381~386 (2012)
- Hanna-Mitchell AT, "Impact of diabetes mellitus on bladder uroepithelial cells", Am J Physiol Regul Integr Comp Physiol, 304, pp.R84~93 (2013)
- Yoshizawa T, "Concomitant alteration in number and affinity of P2X and muscarinic receptors are associated with bladder dysfunction in early stage of diabetic rats", Int Urol Nephrol, 50, pp.451~458 (2018)
- Andersson KE, "Chronic pelvic ischemia : contribution to the pathogenesis of lower urinary tract symptoms(LUTS) : a new target for pharmacological treatment", Low Urin Tract Symptoms, 7, pp.1~8 (2015)
- Andersson KE, "Pharmacological treatment of chronic pelvic ischemia", Ther Adv Urol, 6, pp.105~114 (2014)
- Chancellor MB, "Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder", Clin Ther, 35, pp.1744~1751 (2013)
- Richter V, "J How much confidence do we need in animal experiments? Statistical assumptions in sample size estimation", Appl Anim Welf Sci, 21, pp.325~333 (2018)